Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation
BioElectronics (OTC: BIEL) has appointed Sree Koneru, PhD to its Board of Directors, effective December 3, 2024. The board now comprises three members, including Kelly Whelan (President) and Richard Staelin, PhD (Chairman). Dr. Koneru, currently Director of Program Management at a contract manufacturing organization specializing in medical devices, previously served as VP of Product Development at BioElectronics. His expertise includes neuromodulation device development, prototype creation, clinical evaluation, and regulatory submissions, having secured FDA approvals and CE marking. Dr. Koneru holds a PhD in Biomedical Engineering from SUNY Binghamton.
BioElectronics (OTC: BIEL) ha nominato Sree Koneru, PhD nel suo Consiglio di Amministrazione, con effetto dal 3 dicembre 2024. Il consiglio è ora composto da tre membri, tra cui Kelly Whelan (Presidente) e Richard Staelin, PhD (Presidente del Consiglio). Il Dr. Koneru, attualmente Direttore della Gestione dei Programmi in un'organizzazione di produzione a contratto specializzata in dispositivi medici, ha precedentemente ricoperto il ruolo di VP dello Sviluppo Prodotti in BioElectronics. La sua esperienza include lo sviluppo di dispositivi di neuromodulazione, la creazione di prototipi, la valutazione clinica e le sottomissioni regolatorie, avendo ottenuto approvazioni dalla FDA e marcature CE. Il Dr. Koneru possiede un PhD in Ingegneria Biomedica presso la SUNY Binghamton.
BioElectronics (OTC: BIEL) ha nombrado a Sree Koneru, PhD en su Junta Directiva, con efecto a partir del 3 de diciembre de 2024. La junta ahora está compuesta por tres miembros, incluyendo a Kelly Whelan (Presidenta) y Richard Staelin, PhD (Presidente de la Junta). El Dr. Koneru, actualmente Director de Gestión de Programas en una organización de fabricación por contrato especializada en dispositivos médicos, anteriormente fue VP de Desarrollo de Productos en BioElectronics. Su experiencia incluye el desarrollo de dispositivos de neuromodulación, la creación de prototipos, la evaluación clínica y las presentaciones regulatorias, habiendo obtenido aprobaciones de la FDA y la marcación CE. El Dr. Koneru tiene un PhD en Ingeniería Biomédica de SUNY Binghamton.
BioElectronics (OTC: BIEL)는 Sree Koneru, PhD를 이사로 임명하였으며, 이는 2024년 12월 3일부터 유효합니다. 이사회의 구성원은 이제 Kelly Whelan(회장)과 Richard Staelin, PhD(이사회 의장)를 포함하여 총 3명입니다. 현재 의료기기를 전문으로 하는 계약 제조 조직에서 프로그램 관리 이사를 맡고 있는 Koneru 박사는 이전에 BioElectronics에서 제품 개발 부사장으로 재직하였습니다. 그의 전문 분야는 신경 조절 장치 개발, 프로토타입 제작, 임상 평가 및 규제 제출로, FDA 승인 및 CE 마크를 확보한 경력이 있습니다. Koneru 박사는 SUNY Binghamton에서 생물 의공학 박사 학위를 취득하였습니다.
BioElectronics (OTC: BIEL) a nommé Sree Koneru, PhD au sein de son Conseil d'Administration, avec effet à partir du 3 décembre 2024. Le conseil est désormais composé de trois membres, dont Kelly Whelan (Présidente) et Richard Staelin, PhD (Président du Conseil). Le Dr Koneru, actuellement Directeur de la Gestion des Programmes dans une organisation de fabrication sous contrat spécialisée dans les dispositifs médicaux, a précédemment occupé le poste de VP du Développement Produit chez BioElectronics. Son expertise inclut le développement de dispositifs de neuromodulation, la création de prototypes, l'évaluation clinique et les soumissions réglementaires, ayant obtenu des approbations de la FDA et le marquage CE. Le Dr Koneru possède un PhD en Ingénierie Biomédicale de la SUNY Binghamton.
BioElectronics (OTC: BIEL) hat Sree Koneru, PhD in seinen Vorstand berufen, mit Wirkung zum 3. Dezember 2024. Der Vorstand besteht nun aus drei Mitgliedern, darunter Kelly Whelan (Präsidentin) und Richard Staelin, PhD (Vorsitzender). Dr. Koneru, der derzeit Direktor für Programmmanagement in einer Auftragsfertigungsorganisation ist, die auf medizinische Geräte spezialisiert ist, war zuvor VP für Produktentwicklung bei BioElectronics. Seine Expertise umfasst die Entwicklung von Neuromodulationsgeräten, die Erstellung von Prototypen, klinische Bewertungen und regulatorische Einreichungen, wobei er FDA-Zulassungen und CE-Kennzeichnungen erhalten hat. Dr. Koneru hat einen PhD in Biomedizintechnik von der SUNY Binghamton.
- Previous experience as VP of Product Development at BioElectronics brings valuable insider knowledge
- Track record of successful FDA approvals and CE marking achievements
- Expertise in medical device development and neuromodulation technology
- Strong academic background with PhD in Biomedical Engineering
- None.
FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD.
"We are honored to welcome Sree Koneru to the Board. Sree brings a rich depth of experience in medical device development. We welcome his insight as we execute our strategy," said Kelly Whelan, President of BioElectronics Corporation.
"I am honored to join the Board of Directors at BioElectronics, a company at the forefront of innovations in neuromodulation," said Sree Koneru, "The Company’s role in pioneering non-pharmacological solutions for pain management and other chronic disease states, aligns with my passion for improving lives through advances in neuromodulation technology. I look forward to contributing to the success and transformative impact of the incredible technology manufactured and distributed by BioElectronics Corporation."
"As we continue to pursue our mission of focusing on R&D aimed at delivering non-pharmacological solutions for acute, chronic and neuropathic pain, Sree is the ideal addition to our Board to help guide our growth as we scale efficiently, while also reaching new markets," said Richard Staelin, PhD, Chairman of the Board of BioElectronics Corporation. "We are thrilled to have Sree join the Board, and we look forward to working together."
Dr. Koneru is Director of Program Management for a contract manufacturing organization that specializes in the design & development of wearable and implantable active electronic medical devices. In his previous role, Sree served as the VP of Product Development for BioElectronics Corporation, where he was responsible for prototype development, physiological testing/clinical evaluation, and regulatory submissions, culminating in several approvals from the US FDA and a CE marking. He also managed the product life cycle from conception to retail launch for domestic and international channel partners.
Sree obtained his doctoral degree in Biomedical Engineering ('15) from the State University of New York at Binghamton, NY- USA. He has a background in bringing Neuromodulation (Electroceuticals) medical devices to market, with research expertise in investigating physiological responses (prototype development and clinical research) of pulsed radiofrequency electromagnetic fields. His vision is to be an industry leader in developing transcutaneous, percutaneous, implantable, and electromagnetic neuromodulation technologies, intended to treat chronic diseases.
Certain information set forth in this release contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
IR@bielcorp.com
FAQ
When did Sree Koneru join BioElectronics (BIEL) Board of Directors?
How many members are on BioElectronics (BIEL) Board of Directors after Koneru's appointment?
What was Sree Koneru's previous role at BioElectronics (BIEL)?
What are Sree Koneru's qualifications for joining BioElectronics (BIEL)?
